Weight-loss drugs fight it out

Share this article:

The battle of the bulge got bigger in the past week. First, Eisai announced Friday that it was adding 200 contract sales reps to tout the benefits of the prescription weight-loss drug Belviq. This means that 600 personnel will be able to talk to doctors about the benefits of the slimming drug, which, like competitor Qsymia by Vivus, works when accompanied by dietary and activity changes.

The enlarged sales force is expected to be active by July 1.

Then, Reuters reported Friday that generics maker Actavis wants to get into the Qsymia business and is using claims of invalid patents as part of its marketing application to make generics of the slimming drug, which has a 2020 patent expiration date attached to it.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.